Immix Biopharma, Inc. IMMX Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s share based compensation arrangement by share based payment award non option equity instruments outstanding number.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s share based compensation arrangement by share based payment award non option equity instruments outstanding number?
- Immix Biopharma, Inc. (IMMX) reported share based compensation arrangement by share based payment award non option equity instruments outstanding number of $5.52M in Q1 2026.
- How has Immix Biopharma, Inc.'s share based compensation arrangement by share based payment award non option equity instruments outstanding number changed year-over-year?
- Immix Biopharma, Inc.'s share based compensation arrangement by share based payment award non option equity instruments outstanding number increased by 138.8% year-over-year, from $2.31M to $5.52M.
- What is the long-term trend for Immix Biopharma, Inc.'s share based compensation arrangement by share based payment award non option equity instruments outstanding number?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s share based compensation arrangement by share based payment award non option equity instruments outstanding number has grown at a 97.6% compound annual growth rate (CAGR), from $366K to $5.58M.